Newborn Screening
Newborn genetic screening is a state health program that helps to identify manageable genetic or congenital disorders and potentially treatable disease in newborn infants within days of birth. Early intervention to treat these disorders can eliminate or reduce symptoms that might otherwise cause a lifetime of disability including mental retardation.
- 3-hydroxy-3-methylglutaric aciduria - See 3-hydroxy-3-methylglutaric aciduria (HMG)
- 3-hydroxy-3-methylglutaric aciduria (HMG)
- Acyl-coa dehydrogenase, medium-chain, deficiency of
- Acyl-coa dehydrogenase, short-chain, deficiency of
- Biotinidase deficiency
- Congenital toxoplasmosis
- Cystic fibrosis
- Glutaric acidemia type 1
- Glutaric acidemia type 2
- HMG - See 3-hydroxy-3-methylglutaric aciduria (HMG)
- Homocystinuria
- Hurler syndrome - See Mucopolysaccharidosis Type I
- Hurler-Scheie syndrome - See Mucopolysaccharidosis Type I
- Isovaleric acidemia
- Krabbe disease
- Maple syrup urine disease
- MCAD deficiency - See Acyl-coa dehydrogenase, medium-chain, deficiency of
- MPS I - See Mucopolysaccharidosis Type I
- MPS I H - See Mucopolysaccharidosis Type I
- MPS I H-S - See Mucopolysaccharidosis Type I
- MPS I S - See Mucopolysaccharidosis Type I
- mucopolysaccharidosis I - See Mucopolysaccharidosis Type I
- Mucopolysaccharidosis Type I
- Ornithine transcarbamylase (OTC) deficiency
- Phenylketonuria
- PKU - See Phenylketonuria
- Propionic acidemia
- SCADD - See Acyl-coa dehydrogenase, short-chain, deficiency of
- Scheie syndrome - See Mucopolysaccharidosis Type I
- Sickle-cell anemia
- TT1 - See Tyrosinemia Type I
- Turner syndrome
- Tyrosinemia Type I
- Tyrosinemia Type II
- Wilson disease
